Thyroid Follicular Cell Signaling and Development in Humans
Project Number5R01DK105029-09
Former Number5R01DK105029-07
Contact PI/Project LeaderHOLLENBERG, ANTHONY N Other PIs
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Project Summary
The development of the thyroid gland from anterior endoderm is an essential step in development that allows for
the production of thyroid hormones around week 12 in utero in humans. Unfortunately, in about 1/4000 births
genetic mutations that affect this development pathway lead to congenital hypothyroidism requiring lifelong
thyroid hormone replacement therapy. Thus, a better understanding of thyroid follicular cell development could
lead to a process where genetic editing and cellular therapy could provide treatment for congenital
hypothyroidism (CH). Our work in this area has utilized a directed differentiation approach and has identified
bone morphogenic protein and fibroblast growth factor as key mediators of thyroid follicular cell lineage
development across species resulting in functional murine thyroid follicular cells that can rescue athyreotic mice.
In this proposal, we now turn our attention exclusively to human thyroid follicular cell development and propose
three Specific Aims that will allow for the pre-clinical development of functioning human thyroid follicular cells
derived from human induced pluripotent stem cells (iPSCs), In the first Aim we will utilize a novel lineage tracing
methodology to understand how developing human thyroid follicular acquire their cell fate and to ensure that the
process in iPSC parallels that in vivo. In the second Aim we will prove that the human thyroid follicular cells
derived from iPSCs are fully able to produce thyroid hormones in vitro and can be transplanted into
immunodeficient athyreotic mice to rescue their hypothyroidism. Finally, in the third Aim we will demonstrate pre-
clinically that derived iPSCs from a patient with CH can be genetically corrected and re-introduced via transplant
to function normally. Together completion of these Aims will provide key insight into the possibilities of iPSC
derived cellular therapy for the treatment of CH and enhance our understanding of the development endodermal-
derived tissues in humans.
Public Health Relevance Statement
Narrative
Thyroid hormone (TH) is a critical mediator of fetal development and then essential for normal health during
adulthood. Currently, therapy for those with hypothyroidism (either congenital or acquired later in life) is with
L-thyroxine and many individuals on therapy do not feel adequately replaced, in this proposal we put forward
experiments designed to develop thyroid hormone secreting follicular cells from human induced pluripotent
stem cells. Completion of this work will give us significant insight into the developmental biology of the human
thyroid and potentially offer a unique and powerful approach to treat hypothyroidism in humans, furthermore,
the development of follicular cells from progenitor cells will give us an ideal model to better understand many
diseases of the thyroid that affect human health.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
01-May-2023
Project End Date
30-April-2026
Budget Start Date
01-May-2024
Budget End Date
30-April-2026
Project Funding Information for 2024
Total Funding
$395,999
Direct Costs
$239,999
Indirect Costs
$156,000
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Diabetes and Digestive and Kidney Diseases
$395,999
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK105029-09
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK105029-09
Patents
No Patents information available for 5R01DK105029-09
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK105029-09
Clinical Studies
No Clinical Studies information available for 5R01DK105029-09
News and More
Related News Releases
No news release information available for 5R01DK105029-09
History
No Historical information available for 5R01DK105029-09
Similar Projects
No Similar Projects information available for 5R01DK105029-09